Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 3
2005 8
2006 5
2007 2
2008 3
2009 4
2010 4
2011 1
2012 1
2013 7
2014 4
2015 2
2016 7
2017 17
2018 16
2019 18
2020 23
2021 19
2022 18
2023 16
2024 18
2025 33
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice.
Iwai S, Kaji K, Nishimura N, Kubo T, Tomooka F, Shibamoto A, Suzuki J, Tsuji Y, Fujinaga Y, Kitagawa K, Namisaki T, Akahane T, Yoshiji H. Iwai S, et al. Among authors: namisaki t. Biochim Biophys Acta Mol Basis Dis. 2023 Oct;1869(7):166770. doi: 10.1016/j.bbadis.2023.166770. Epub 2023 Jun 3. Biochim Biophys Acta Mol Basis Dis. 2023. PMID: 37276988 Free article.
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Hirschfield GM, Bowlus CL, Jones DEJ, Kremer AE, Mayo MJ, Tanaka A, Andreone P, Jia J, Jin Q, Macías-Rodríguez RU, Cobitz AR, Currie BM, Gorey C, Lazic I, Podmore D, Ribeiro A, Shannon JB, Swift B, McLaughlin MM, Levy C; GLISTEN Study Group. Hirschfield GM, et al. Lancet Gastroenterol Hepatol. 2026 Jan;11(1):22-33. doi: 10.1016/S2468-1253(25)00192-X. Epub 2025 Oct 28. Lancet Gastroenterol Hepatol. 2026. PMID: 41173016 Clinical Trial.
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J, Verbinnen T, Lenz O, Shukla U, Biermer M; REEF-1 Study Group. Yuen MF, et al. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37442152 Clinical Trial.
Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey.
Miwa T, Tsuruoka M, Ueda H, Abe T, Inada H, Yukawa-Muto Y, Ohara M, Arai T, Tamai Y, Isoda H, Tadokoro T, Hanai T, Ito T, Tamaki N, Sakamaki A, Aoki Y, Tada F, Yoshio S, Takahashi H, Morishita A, Ishikawa T, Inoue J, Suda G, Ogawa C, Atsukawa M, Hiraoka A, Kuroda H, Namisaki T, Honda T, Kawaguchi T, Tanaka Y, Terai S, Ikegami T, Yoshiji H, Iwasa M, Shimizu M. Miwa T, et al. Among authors: namisaki t. J Gastroenterol. 2025 Jul;60(7):866-876. doi: 10.1007/s00535-025-02232-0. Epub 2025 Mar 7. J Gastroenterol. 2025. PMID: 40053108 Free PMC article.
Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial.
Arase Y, Okubo T, Arai T, Abe M, Namisaki T, Uojima H, Matsumoto K, Kakisaka K, Setsu T, Mishima Y, Tsuruya K, Hirose S, Deguchi R, Shiraishi K, Atsukawa M, Ikegami T, Honda A, Terai S, Yoshiji H, Komori A, Tanaka A, Kagawa T. Arase Y, et al. Among authors: namisaki t. Hepatol Commun. 2025 Oct 7;9(11):e0827. doi: 10.1097/HC9.0000000000000827. eCollection 2025 Nov 1. Hepatol Commun. 2025. PMID: 41056494 Free PMC article. Clinical Trial.
Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut-Liver Axis and Epiregulin-IL-8-Associated Angiogenesis.
Nishimura N, Kaji K, Nishimura N, Hanatani J, Nakatani T, Oyama M, Shibamoto A, Tsuji Y, Kitagawa K, Sato S, Namisaki T, Tamaoki S, Yoshiji H. Nishimura N, et al. Among authors: namisaki t. Int J Mol Sci. 2025 Jul 12;26(14):6710. doi: 10.3390/ijms26146710. Int J Mol Sci. 2025. PMID: 40724957 Free PMC article.
Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity.
Matsuda T, Kaji K, Nishimura N, Asada S, Koizumi A, Tanaka M, Yorioka N, Tsuji Y, Kitagawa K, Sato S, Namisaki T, Akahane T, Yoshiji H. Matsuda T, et al. Among authors: namisaki t. Heliyon. 2024 Sep 27;10(19):e38647. doi: 10.1016/j.heliyon.2024.e38647. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39398008 Free PMC article.
215 results